Sort by
Refine Your Search
-
Listed
-
Category
-
Country
-
Program
-
Field
-
Dalhousie University | Halifax Mid Harbour Nova Scotia Provincial Government, Nova Scotia | Canada | 9 days ago
Chairs program whom they hope to work with. To hire a Impact+ Emerging Leader, Dalhousie must first secure a Canada Impact+ Research Chairs in a complementary research area. Learn more: https
-
of hire, obtain a ONS/ONCC Chemotherapy Immunotherapy Certificate. Within three (3) years of hire, obtain Oncology Certified Nurse (OCN®) or Bone Marrow Transplant Certified Nurse (BMTCN®) or 36 continued
-
University of California, San Francisco | San Francisco, California | United States | about 2 months ago
(Hourly Rate). To learn more about the benefits of working at UCSF, including total compensation, please visit: https://ucnet.universityofcalifornia.edu/compensation-and-benefits/index.html Required
-
/research growth and development in this area. Ideal candidates will demonstrate a track record of impactful research contributions in one or more of the following key areas: cancer biology, immunotherapy
-
Hutch is the only National Cancer Institute-designated cancer center in Washington. With a track record of global leadership in bone marrow transplantation, HIV/AIDS prevention, immunotherapy and COVID-19
-
Instituto de Investigação e Inovação em Saúde da Universidade do Porto (i3S) | Portugal | 26 days ago
the administration of anti-PSGL-1 with anti-CD20, which is a standard targeted immunotherapy (rituximab) for B-cell lymphomas, versus each one alone. Also, we will treat A20 lymphoma mice with anti-PSGL-1 in
-
and immunology research is available at the University of California, San Francisco in the Lee Laboratory. The Lee Lab works on cancer immunotherapy is part of the Department of Radiation Oncology and
-
. This position manages scientific, administrative, and operational functions for a dynamic research team investigating tumor immunology and novel immunotherapy approaches for pancreatic and other solid organ
-
Treg cell immunotherapy. A key emphasis of their work is on treating graft-versus-host disease (GVHD) and inducing immune tolerance for transplantation and autoimmunity. The Meyer Lab is seeking a
-
on mechanisms regulating the activation of cells of the immune system, cancer immunotherapy with the use of monoclonal antibodies, and effector cells including cells modified with chimeric antigen receptors (CAR